Wayne H Winegarden
Commentary
Drug Pricing Reforms Should Expand Choice, Not Government Control
As President Biden‘s recent State of the Union address made clear, drug pricing will remain a top policy issue for the foreseeable future. The president is correct that something must be done, but his proposals are wrongheaded and will only make things worse. Instead of focusing on government price controls, Congress ...
Business & Economics
NEW STUDY: Rejecting Push to Restrict Gig Entrepreneurship Key to Driving Innovation, Economic Growth, Higher Incomes
Amid a renewed push in Congress and states to enact new gig economy restrictions following California’s controversial AB 5, a new study released today by the nonpartisan Pacific Research Institute finds that enacting these harmful laws would hinder innovation and restrict people’s ability to become entrepreneurs and provide for their ...
Business & Economics
The Empty Case for Stakeholder Capitalism and ESG Investing
Instead of promoting responsible behavior, these practices undermine the principles of good corporate governance. Larry Fink, the chairman and CEO of BlackRock, is selling the idea that the world economy must embrace stakeholder capitalism and environmental, social, and governance (ESG) investing. Don’t worry, though, he wants you to know that stakeholder ...
Drug Prices
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics ...
Business & Economics
Controlling Inflation Requires A Better Policy Mix, Not Business Scapegoating
Thanks to errant fiscal and monetary policies, consumer prices continued their relentless climb in December. Just as predictably, politicians seem to be more interested in “rounding up the usual suspects” rather than implementing the right policy mix that would rein in inflation. Political fecklessness in face of rising prices is ...
Featured
The Fundamental Flaws of the Third-Party Payer System
Part 1 of the Coverage Denied series documented how distortions in the U.S. healthcare system turned the important financial risk management service of health insurance into a barrier to care and an important driver of health care inflation. The insurance industry’s adverse impact on costs is ironic given its current ...
Featured
NEW BRIEF: 340B Hospitals More Profitable, Provide Less Charity Care, Receive Unwarranted Subsidies
So-called 340B hospitals whose mission is to help the vulnerable are more profitable and provide less charity care, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market think tank. Click to download “Profiting from 340B” “The ...
Health Care
NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars
Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market ...
Featured
New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes
Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system ...
Drug Pricing
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
Drug Pricing Reforms Should Expand Choice, Not Government Control
As President Biden‘s recent State of the Union address made clear, drug pricing will remain a top policy issue for the foreseeable future. The president is correct that something must be done, but his proposals are wrongheaded and will only make things worse. Instead of focusing on government price controls, Congress ...
NEW STUDY: Rejecting Push to Restrict Gig Entrepreneurship Key to Driving Innovation, Economic Growth, Higher Incomes
Amid a renewed push in Congress and states to enact new gig economy restrictions following California’s controversial AB 5, a new study released today by the nonpartisan Pacific Research Institute finds that enacting these harmful laws would hinder innovation and restrict people’s ability to become entrepreneurs and provide for their ...
The Empty Case for Stakeholder Capitalism and ESG Investing
Instead of promoting responsible behavior, these practices undermine the principles of good corporate governance. Larry Fink, the chairman and CEO of BlackRock, is selling the idea that the world economy must embrace stakeholder capitalism and environmental, social, and governance (ESG) investing. Don’t worry, though, he wants you to know that stakeholder ...
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics ...
Controlling Inflation Requires A Better Policy Mix, Not Business Scapegoating
Thanks to errant fiscal and monetary policies, consumer prices continued their relentless climb in December. Just as predictably, politicians seem to be more interested in “rounding up the usual suspects” rather than implementing the right policy mix that would rein in inflation. Political fecklessness in face of rising prices is ...
The Fundamental Flaws of the Third-Party Payer System
Part 1 of the Coverage Denied series documented how distortions in the U.S. healthcare system turned the important financial risk management service of health insurance into a barrier to care and an important driver of health care inflation. The insurance industry’s adverse impact on costs is ironic given its current ...
NEW BRIEF: 340B Hospitals More Profitable, Provide Less Charity Care, Receive Unwarranted Subsidies
So-called 340B hospitals whose mission is to help the vulnerable are more profitable and provide less charity care, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market think tank. Click to download “Profiting from 340B” “The ...
NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars
Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market ...
New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes
Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system ...
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
